GABAB receptor Inhibitors
1 drugsAbout GABAB receptor
The GABA<sub>B</sub> receptor is an inhibitory G protein-coupled receptor activated by GABA, the primary mediator of neuronal inhibition in the central nervous system. It plays a significant role in various physiological processes.
The GABA<sub>B</sub> receptor is a target for drug development, though there is currently no genetic evidence data available linking it to specific diseases. Further research could reveal new therapeutic opportunities in areas like epilepsy and pain management.
GABA<sub>B</sub> receptor is targeted by one FDA-approved drug, GABLOFEN, a small molecule. This drug, marketed by PIRAMAL CRITICAL, was first approved in 2010 and is classified within the 'other' therapeutic area.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Rumination Syndrome with only 1 trials.
GABAB receptor Genetic Evidence Strong
There is no genetic evidence data available for the GABA<sub>B</sub> receptor.
Lack of genetic validation may increase the risk of clinical failure; consider prioritizing targets with stronger genetic support.
Evidence Across Diseases
8 totalGWAS and other genetic studies link GABBR1 to 8 diseases.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top GABAB receptor Drugs
PIRAMAL CRITICAL is the only company with an approved drug targeting the GABA<sub>B</sub> receptor.
The market is highly concentrated, suggesting high barriers to entry or limited commercial opportunity for new GABA<sub>B</sub> receptor modulators.
GABAB receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets GABAB receptor, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage in modulating GABA<sub>B</sub> receptor activity.
GABAB receptor Clinical Trials 54 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 7 | 6 | 1 | 0 | 86% |
| Phase 2 | 21 | 13 | 5 | 3 | 72% |
| Phase 3 | 10 | 8 | 1 | 1 | 89% |
| Phase 4 | 16 | 9 | 5 | 1 | 64% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
GABAB receptor Drug Approval Timeline (2010 - 2010)
The first and most recent drug approval for a GABA<sub>B</sub> receptor target was GABLOFEN in 2010.
The absence of recent approvals suggests a saturated market or challenges in developing new GABA<sub>B</sub> receptor-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 37 clinical trials targeting GABAB receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities